We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

30% more call options, than puts

Call options by funds: $21.6M | Put options by funds: $16.6M

14% more capital invested

Capital invested by funds: $2.22B → $2.54B (+$321M)

6% more funds holding

Funds holding: 212 → 224 (+12)

1.99% more ownership

Funds ownership: 88.53% → 90.53% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 76

Holders
224
Holders Change
+12
Holders Change %
+5.66%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
72
Reduced
76
Closed
18
Calls
$21.6M
Puts
$16.6M
Net Calls
+$4.98M
Net Calls Change
-$3.09M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$84.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$31.7M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$29.5M
5
JP Morgan Chase
JP Morgan Chase
New York
+$15.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$30.5M
3
BlackRock
BlackRock
New York
-$25.2M
4
State Street
State Street
Massachusetts
-$21.7M
5
Goldman Sachs
Goldman Sachs
New York
-$21.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
FT
101
Fiduciary Trust
Massachusetts
$1.22M -$1.24K -25 -0.1%
PA
102
Profund Advisors
Maryland
$1.21M -$272K -5,465 -18%
AIG
103
American International Group
New York
$1.2M +$15.2K +305 +1%
New York State Common Retirement Fund
104
New York State Common Retirement Fund
New York
$1.05M -$291K -5,842 -21%
DekaBank Deutsche Girozentrale
105
DekaBank Deutsche Girozentrale
Germany
$1.05M – – –
HCA
106
Harbor Capital Advisors
Illinois
$990K +$1.05M +21,053 New
EAM
107
EFG Asset Management
Oregon
$987K +$1.04M +21,003 New
Tudor Investment Corp
108
Tudor Investment Corp
Connecticut
$979K -$522K -10,500 -34%
SSA
109
Schonfeld Strategic Advisors
New York
$979K +$1.04M +20,823 New
EIM
110
Essex Investment Management
Massachusetts
$957K +$1.01M +20,360 New
Capital Fund Management (CFM)
111
Capital Fund Management (CFM)
France
$942K -$86K -1,728 -8%
IBT
112
International Biotechnology Trust
United Kingdom
$939K +$995K +20,000 New
IA
113
Inspire Advisors
Idaho
$919K +$67.8K +1,363 +7%
EGM
114
Engineers Gate Manager
New York
$909K +$962K +19,340 New
VF
115
Virtu Financial
New York
$837K +$885K +17,793 New
MAM
116
Martingale Asset Management
Massachusetts
$795K – – –
HF
117
HRT Financial
New York
$794K -$1M -20,180 -54%
SG Americas Securities
118
SG Americas Securities
New York
$788K +$282K +5,668 +51%
CSS
119
Cubist Systematic Strategies
Connecticut
$756K -$412K -8,282 -34%
Royal Bank of Canada
120
Royal Bank of Canada
Ontario, Canada
$741K +$45.7K +918 +6%
ASRS
121
Arizona State Retirement System
Arizona
$710K -$20.8K -418 -3%
State Board of Administration of Florida Retirement System
122
State Board of Administration of Florida Retirement System
Florida
$705K -$81.6K -1,640 -10%
Hudson Bay Capital Management
123
Hudson Bay Capital Management
Connecticut
$705K -$3.23M -65,000 -81%
OC
124
Oppenheimer & Co
New York
$697K +$737K +14,813 New
Teacher Retirement System of Texas
125
Teacher Retirement System of Texas
Texas
$686K -$95.2K -1,914 -12%
3 4
5
6 7

SAGE Hedge Fund Activity: Q2 2023 in Review

224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.

  • 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
  • Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
  • 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
  • The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2023.